Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
213.20
+1.31 (+0.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
39
40
Next >
Biogen's Earnings Outlook
July 19, 2022
Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Wednesday, 2022-07-20. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report...
Via
Benzinga
Analyst Ratings for Biogen
July 18, 2022
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:
Via
Benzinga
Bank Of America And Goldman Sachs Split On Earnings Reports, Possibly Putting Bank Rally In Jeopardy
July 18, 2022
(Monday Market Open) Investors around the globe appear to be starting the new trading week with a positive attitude as Asian and European markets traded higher overnight helping to boost U.S. equity...
Via
Benzinga
Why Scholar Rock Shares Are Trading Higher Today
June 17, 2022
Via
Benzinga
Tesla, Twitter, Goldman Among Headline Earnings Of Unfolding Week: Here Are The Key Earnings Ahead
July 17, 2022
The June quarter reporting season is entering its second week, with the focus gradually shifting from banks to technology companies.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 15, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Another Way To Understand Market Momentum
July 15, 2022
(Friday Market Open) U.S. equity futures moved higher early Friday as investors digested better-than-expected June retail sales data and China’s worst GDP numbers since the start of the pandemic. Later...
Via
Benzinga
Hot Inflation And Earnings Misses Weigh On Equity Futures
July 14, 2022
(Thursday Market Open) The equity markets may take another hit today as JPMorgan Chase (NYSE: JPM) and Morgan Stanley (NYSE: MS) kicked off a new earnings season with a couple of misses as eq
Via
Benzinga
Looking Into Biogen's Recent Short Interest
July 14, 2022
Biogen's (NASDAQ:BIIB) short percent of float has fallen 4.95% since its last report. The company recently reported that it has 2.52 million shares sold short, which is 1.73% of...
Via
Benzinga
The Fed's Pickle: Whether to Raise Rates to Fight Inflation While Increasing Recession Chances
July 13, 2022
(Wednesday Market Open) The June Consumer Price Index (CPI) came in much hotter than expected, and equity index futures tumbled before the open.
Via
Benzinga
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years
July 12, 2022
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.87% on an annualized basis producing an average annual return of 10.15%. Currently, Biogen has a market capitalization of...
Via
Benzinga
Pliant Therapeutics Stock Just Doubled And Hit A 10-Month High — Here's Why
July 11, 2022
The company's IPF treatment is proving itself where others didn't.
Via
Investor's Business Daily
The 3 Leaders of the Gene Editing Revolution
July 08, 2022
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.
Via
InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.
Via
InvestorPlace
7 Best Biotech Stocks to Buy in July 2022
July 08, 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.
Via
InvestorPlace
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
July 06, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
3 Biotech Stocks to Sell Now
July 05, 2022
These biotech stocks remain vulnerable to more downside. Their charts remain broken and resistance looms ominously overhead.
Via
InvestorPlace
EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
June 30, 2022
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.
Via
Benzinga
Peering Into Biogen's Recent Short Interest
June 28, 2022
Biogen's (NASDAQ:BIIB) short percent of float has risen 9.27% since its last report. The company recently reported that it has 2.41 million shares sold short, which is 1.65% of...
Via
Benzinga
Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today
June 27, 2022
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.63% on an annualized basis producing an average annual return of 10.11%. Currently, Biogen has a market capitalization of...
Via
Benzinga
7 Biotech Stocks With Key Catalysts Coming in July
June 27, 2022
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
June 17, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Roche's Alzheimer's Failures Keep Piling Up; Can The Stock Recover?
June 16, 2022
Roche hoped to prevent Alzheimer's disease in patients with a genetic defect.
Via
Investor's Business Daily
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
June 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement
June 15, 2022
Via
Benzinga
Analyzing Biogen's Short Interest
June 10, 2022
Biogen's (NASDAQ:BIIB) short percent of float has risen 8.63% since its last report. The company recently reported that it has 2.20 million shares sold short, which is 1.51% of...
Via
Benzinga
$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
June 09, 2022
Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.47% on an annualized basis producing an average annual return of 9.5%. Currently, Biogen has a market capitalization of...
Via
Benzinga
7 No-Brainer Biotech Stocks to Add to Your Buy List
June 09, 2022
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile.
Via
InvestorPlace
Quant Ratings Updated on 66 Stocks
June 06, 2022
Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10.
Via
InvestorPlace
Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same
June 01, 2022
Sage and Biogen say their MDD drug met every goal in a study of postpartum women.
Via
Investor's Business Daily
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.